Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GlaxoSmithKline in pair of deals

GlaxoSmithKline (LSE:GSK; GSK) announced two deals on Monday, partnering with OncoMed to develop antibodies targeting cancer stem cells and with Galapagos to

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE